Rate and predictors of non-response to first-line antipsychotic treatment in first-episode schizophrenia

Human Psychopharmacology
Bonginkosi ChilizaRobin Emsley

Abstract

The goals of this study were to (i) estimate the rate of non-response to first-line treatment in first-episode schizophrenia, (ii) evaluate other outcomes associated with symptom non-response and (iii) identify demographic, baseline clinical and early treatment response predictors of non-response. This was a single-site, longitudinal cohort study assessing the effects of treatment with flupenthixol decanoate according to a standardised protocol over 12 months in patients with schizophrenia, schizophreniform and schizo-affective disorders. Of 126 patients who received at least one dose of study medication, 84 (67%) completed the study. Fifteen (12%) met our predefined criteria for non-response. Non-responders were younger and at baseline had more prominent disorganised symptoms, poorer social and occupational functioning, poorer quality of life for psychological, social and environmental domains, more prominent neurological soft signs (NSS) and lower body mass index. At endpoint, the non-responders were characterised by higher levels of symptomatology in all domains, poorer functional outcome, poorer quality of life and greater cognitive impairments. They also had more prominent NSS and lower body mass index. The strongest predi...Continue Reading

References

Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Apr 1, 1985·The British Journal of Psychiatry : the Journal of Mental Science·T KolakowskaM Ardern
Jan 1, 1982·Schizophrenia Bulletin·H E Cannon-SpoorR J Wyatt
Jan 1, 1994·Acta Psychiatrica Scandinavica·M BirchwoodM Slade
Jan 1, 1993·Schizophrenia Bulletin·J M Kane, S R Marder
Mar 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J A LiebermanM Woerner
Apr 1, 1997·The American Journal of Psychiatry·H Y MeltzerP A Thompson
Jul 15, 1999·Psychological Medicine·J M AlvirJ A Lieberman
Jun 1, 2000·The American Journal of Psychiatry·D MalaspinaJ M Gorman
Dec 18, 2001·Biological Psychiatry·R R Conley, D L Kelly
Mar 22, 2003·Schizophrenia Research·Robin EmsleyUNKNOWN RIS-INT-35 Early Psychosis Global Working Group
Jun 23, 2004·Journal of Clinical Psychopharmacology·John M Davis, Nancy Chen
Dec 24, 2004·The Journal of Neuropsychiatry and Clinical Neurosciences·Richard D SandersMatcheri S Keshavan
Mar 3, 2005·The American Journal of Psychiatry·Nancy C AndreasenDaniel R Weinberger
Jun 14, 2005·Schizophrenia Research·Guy Chouinard, Howard C Margolese
Sep 21, 2005·Schizophrenia Research·Rahul ManchandaSandra Northcott
Dec 7, 2005·The American Journal of Psychiatry·Silke BachmannJohannes Schröder
Jun 8, 2006·Psychological Medicine·N M MenezesR B Zipursky
Jan 2, 2007·The Journal of Clinical Psychiatry·Robin EmsleyH Jadri Turner
Jul 7, 2007·European Psychiatry : the Journal of the Association of European Psychiatrists·Radovan PrikrylHana Kucerova
Jul 17, 2007·Journal of Clinical Psychopharmacology·Ofer AgidRobert B Zipursky
Aug 3, 2007·International Review of Psychiatry·Mujeeb U ShadAnthony David
Mar 12, 2008·Current Opinion in Psychiatry·Robin EmsleyRenata Schoeman
Jan 13, 2009·Acta Psychiatrica Scandinavica. Supplementum·S LeuchtJ M Kane
Jan 1, 1995·European Psychiatry : the Journal of the Association of European Psychiatrists·S Marder
Nov 6, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bruce J KinonJohn M Kane
Aug 21, 2010·Acta Psychiatrica Scandinavica·Erik SimonsenT H McGlashan
Jan 25, 2011·Expert Opinion on Pharmacotherapy·Scott P Van Sant, Peter F Buckley
Dec 22, 2011·The British Journal of Psychiatry : the Journal of Mental Science·Takefumi SuzukiDavid C Mamo
Mar 27, 2012·Schizophrenia Research·Robin EmsleySrihari Gopal
Nov 23, 2012·Schizophrenia Bulletin·Robert B ZipurskyRobin M Murray
Jan 2, 2013·Journal of Clinical Psychopharmacology·Robin EmsleyLupe Martinez
Feb 5, 2013·The American Journal of Psychiatry·Gary RemingtonMark Sinyor
Feb 20, 2013·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Simon FreyTom Stargardt
Sep 3, 2013·International Clinical Psychopharmacology·James L KennedyJohn C Hornberger

❮ Previous
Next ❯

Citations

Aug 5, 2015·Progress in Neuro-psychopharmacology & Biological Psychiatry·Adrian Andrzej ChrobakDominika Dudek
Sep 24, 2016·Neurocase·Aislinn J WilliamsStephan F Taylor
Sep 20, 2017·Journal of Psychopharmacology·Yusuke NakataMasaomi Iyo
Aug 23, 2017·International Journal of Psychiatry in Clinical Practice·Barbara RemberkFilip Rybakowski
Mar 14, 2019·Frontiers in Psychiatry·Paola BozzatelloPaola Rocca
Oct 4, 2020·Journal of Clinical Psychopharmacology·Sanjana KumarJennifer B Levin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here